Coma Diagnosis and Treatment Market Share

Coma Diagnosis and Treatment Market Scenario

The coma diagnosis & treatment market is expected to reach USD 5,711.78 Million by 2030 at 7.5% CAGR during the forecast period 2022-2030.Coma refers to a state of unconsciousness in which a patient remains unresponsive to anything around them for a prolonged period of time. Depending on the severity of the coma, patient may require life-saving resuscitative measures and once the patient is medically stable, treatments can be used to treat original problem that is causing the coma.

There are various causes of coma such as traumatic brain injuries and are often caused by accidents or acts of violence. Strokes occur due to reduced or interrupted blood supply to the brain which is caused by blocked arteries or a burst blood vessel resulting in a coma. The other main cause of coma is tumors in the brain or brainstem. In some cases overdosing on drugs or alcohol can result in coma. Moreover, people with diabetes, blood sugar levels that become too high (hyperglycemia) or too low (hypoglycemia) causes coma. People who have been rescued from drowning or those who have been resuscitated after a heart attack may not awaken due to lack of oxygen to the brain. Furthermore infections such as encephalitis and meningitis cause swelling or inflammation of the brain, spinal cord or the tissues that surround the brain in severe cases of these infections can result in coma. Moreover, in some cases exposure to toxins, such as carbon monoxide or lead, can cause brain damage and coma.

Increasing prevalence of neurological disorders, increasing investment by biotechnology and pharmaceutical industries in R&D, and rising need for the better treatment methods drive the growth of the market. Moreover, favorable reimbursement policies, increased application and significant investments in the development of new technologies for the treatment of diseases will fuel the market growth during the forecast period

Furthermore, globalization in healthcare has increased the market growth. Established market players in the developed countries leads the globalization by pushing new products and services into the developing countries and emerging economies. 

According to the World Health Organization estimates, neurological disorders are responsible for 4.5%-11% of all illnesses including low or high income economies. This is far higher as compared to the number of respiratory ailments, gastrointestinal disorders, or cancers, and the burden is expected to increase further over the coming years.

However, limited availability of facilities and higher treatment cost may hamper the coma diagnosis & treatment market growth during the forecast period.

Intended Audience

• Pharmaceutical and Biotechnological Companies


• Research and Development (R&D) Companies


• Ambulatory Care Centers


• Academic Institutes and Universities


• Market Research and Consulting Service Providers


• Potential Investors 

Figure: Coma Diagnosis & Treatment Market, By Region Market Share, 2016 (%)

Sources: Annual reports, Press release, White paper, Company presentation

Segmentations

The coma diagnosis & treatment market is segmented on the basis of types, diagnosis, treatment, and end user.

On the basis of the type, it is segmented into toxic- metabolic encephalopathy, anoxic brain injury, persistent vegetative state, locked-in syndrome, and brain death.  

On the basis of diagnosis it is segmented into physical examination, blood test, brain scans, and others. Brain scan is further segmented into computerized tomography (CT) scan, magnetic resonance imaging (MRI) and electroencephalography (EEG).

On the basis of treatment it is segmented into medical treatment, and others.

On the basis of the end user, it is segmented into hospitals & clinics, research laboratories and others.

Regional Analysis

The Americas dominate the coma diagnosis & treatment market owing to well-developed technology, increasing patient population for brain disorder, high health care spending, and increasing government support for research & development. Furthermore, increased R&D activities and the concentration of major companies have fuelled the growth of the coma diagnosis & treatment market in this region.

Europe holds the second position in the coma diagnosis & treatment market owing to the government support for research & development and availability of funds for research. This is expected to continue to drive the European market over the forecasted period. For instance, developed economies such countries such as Germany and France are increasing investment in the healthcare domain and are focusing more on hospital infrastructure.

Asia Pacific is the fastest growing coma diagnosis & treatment market owing to the presence of rapidly developing healthcare technology, increasing stressful life, and high healthcare expenditure. Moreover, increasing patient population in countries like India and South Korea are likely to emerge as the fastest growing market across the globe. Furthermore, increasing demand for quality devices in the healthcare is projected to lead the use of advanced equipment, which, in turn, may increase the coma diagnosis & treatment market growth in this region.  

On the other hand, the Middle East & Africa holds the least share of the coma diagnosis & treatment market owing to less availability of funds, limited medical facilities, and deprived political conditions in Africa.

Key Players

Some of key the players in the market are Fujifilm Holdings (Japan), GE Healthcare (U.S.), Siemens Healthcare(U.S.), Philips Healthcare (U.S.), Shimadzu Corporation (Japan), Toshiba Medical Systems Corporation (Japan),   Carestream Health (U.S.), Nihon Kohden Corporation (Japan), Electrical Geodesics Inc. (U.S.), Masimo Corporation (U.S.), Hologic (U.S.), Esaote (Italy), and others. 

Research Methodology

Sources: Annual reports, Press release, White paper, and Company presentation